APOMORPHINE - SUBLINGUAL (Kynmobi®)

Clinical Indication

Idiopathic Parkinson’s Disease

Date of classification

June 2026

Orange

Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.